Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

All NewsAugust 12, 2025

Novartis’ ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent